IN THE COURT OF COMMON PLEAS OF PHILADELPHIA COUNTY

CIVIL TRIAL DIVISION

DOCKETED
COMPLEX LIT CENTER
JAN 28 2011
J. STEWART

IN RE: RISPERDAL LITIGATION	MARCH TERM, 2010 NO. 296
Plaintiff(s) v. Ortho-McNeil-Janssen Pharmaceuticals, Inc., f/k/a Janssen Pharmaceuticals, Inc., Johnson & Johnson Company, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Exceprta Medica, Inc., and Elsevier Inc., Defendants	

RECEIVED
JAN 28 2011
COMPLEX LIT CENTER

ORDER

AND NOW, this 27th day of January, 2011, upon consideration of Defendants Ortho-McNeil-Janssen Pharmaceuticals, Inc., Johnson & Johnson Company, and Johnson and Johnson Pharmaceutical Research and Development, L.L.C.'s Preliminary Objections to Plaintiffs' First Amended Master Long Form Complaint, and any response thereto, it is hereby **ORDERED:**

1. Paragraphs 39 and 133(h) are stricken from the First Amended Master Long Form Complaint.
2. Defendants' objection to Count X, Conspiracy to violate the Federal Food Drug and Cosmetic Act is **SUSTAINED;** Defendants' objection to Count X, Conspiracy to violate "…parallel state acts and state common law…" is **OVERRULED.**
3. Defendants' objection to all claims brought by Plaintiffs who reside in Connecticut, Louisiana, New Jersey, Ohio and Washington is **OVERRULED** without prejudice to raise as a choice of law issue via summary judgment.
4. All other preliminary objections are **OVERRULED.**

BY THE COURT:

Sandra Mazer Moss, J.

In Re: Risperdal Litiga-ORDER

10030029600028

10100175

COPIES SENT PURSUANT TO Pa.R.C.P. 236(b) D. WILLIAMS 01/31/2011